Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Silicolife Lda maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently faces 1 pending office action. This action is being processed by 1 distinct examiner within 1 distinct art unit, reflecting a concentrated effort in this technical domain. This structure indicates that the company is pursuing a specific set of claims rather than a broad array of applications across different units.
EIX, EMILY FAY is the busiest examiner for this portfolio, holding 1 pending office action. This 1 busiest examiner pending action represents the total workload for Silicolife Lda, making this examiner the primary figure in their current prosecution. The presence of 1 distinct art unit and 1 distinct examiner for the 1 pending office action indicates that the company's immediate IP goals are tied to a single examination process.
In the competitive Biotechnology & Pharmaceuticals sector, this singular focus means the outcome of this specific action is critical. Practitioners should note that the company's strategy is currently centralized under EIX, EMILY FAY. Successfully navigating the 1 pending office action in 1 distinct art unit will be the primary factor in the company's immediate success at the USPTO. The data shows no current diversification across other examiners or units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EIX, EMILY FAY | 1 | 45.5% | +78.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263894 | MICROBIAL PRODUCTION OF TYROSOL AND SALIDROSIDE | EIX, EMILY FAY | 23d overdue |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18263894 | MICROBIAL PRODUCTION OF TYROSOL AND SALIDROSIDE | EIX, EMILY FAY | 1653 | §103 | Final Rejection | 23d overdue | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial